Metropolis Healthcare
Market cap ₹11,711 Cr
- P/E
- 52.35
- Day range
- ₹561.50 – ₹576.80
- 52-week range
- ₹412.25 – ₹609.05
- Volume
- 1.68 L
- Open
- ₹567.00
- Prev close
- ₹567.00
Latest results · Q2 FY27(consolidated)Revenue ₹497 Cr+15.8%Profit ₹75 Cr+42.7%Margin 15.2%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoter pledge went up
1.21% of promoter shares pledged, up from 1.18% · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
METROPOLIS in NSE indices and F&O
Research profile
Composite 66 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.9%
- Graham no.
- ₹139.51
- vs Graham
- -75.3%
- ROE ÷ P/B
- 1.9%
- 12-1 mom.
- +9.6%
- Return / vol
- 0.57
- Magic Formula
- #416
- Piotroski
- 6/6
- FCF yield
- 2.6%
Appears in 9 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Metropolis HealthcareMETROPOLIS | ₹11,711 Cr | 52.35 | 7.26 | 13.4% | 18.0% | 27.0% | 0.16 | +15.9% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 6h agoHeadlines about Metropolis Healthcare from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 51.6
- Price / Book
- 7.13
- ROE (FY26)
- 13.4%
- ROCE (latest year)
- 18%
- Dividend yield
- 0.35%
Moving averages (NSE)
- 20-day
- ₹558.07
- Price above
- 50-day
- ₹561.11
- Price above
- 200-day
- ₹526.97
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- FII
- Public
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 20 Mar 2026: earlier bars are per pre-bonus share.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 291 | 331 | 313 | 350 | 323 | 345 | 386 | 429 | 406 | 425 | 450 | 497 |
| Expenses | 226 | 251 | 235 | 260 | 251 | 283 | 296 | 321 | 311 | 317 | 339 | 363 |
| Operating Profit | 65 | 80 | 79 | 90 | 72 | 62 | 90 | 108 | 95 | 108 | 111 | 134 |
| OPM % | 22% | 24% | 25% | 26% | 22% | 18% | 23% | 25% | 23% | 25% | 25% | 27% |
| Other Income | 2 | 3 | 2 | 3 | 3 | 7 | 8 | 1 | 0 | 8 | 5 | 8 |
| Interest | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 8 | 6 | 7 |
| Depreciation | 25 | 26 | 26 | 27 | 28 | 29 | 31 | 32 | 32 | 39 | 32 | 33 |
| Profit before tax | 37 | 51 | 51 | 61 | 42 | 36 | 61 | 71 | 57 | 70 | 78 | 102 |
| Tax % | 26% | 28% | 25% | 24% | 26% | 19% | 26% | 26% | 26% | 27% | 27% | 26% |
| Net Profit | 27 | 37 | 38 | 47 | 31 | 29 | 45 | 53 | 42 | 51 | 57 | 75 |
| EPS in Rs | ₹1.33 | ₹1.78 | ₹1.85 | ₹2.27 | ₹1.53 | ₹1.41 | ₹2.17 | ₹2.54 | ₹2.00 | ₹2.46 | ₹2.73 | ₹3.63 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-7 days since Mar 2021
-8 days since Mar 2021
-14 days since Mar 2021
-1 days since Mar 2021
-6 days since Mar 2021
Strengths, risks & growth
Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
Strengths
None flagged by the checklist.
Risks
- Stock is trading at 7.26 times its book value
- Promoter holding has decreased over last quarter: -1.04%
- The company has delivered a poor sales growth of 10.5% over past five years.
- Company has a low return on equity of 12.5% over last 3 years.
Compounded Sales Growth
- 10 Years
- +13%
- 5 Years
- +11%
- 3 Years
- +13%
- TTM
- +20%
Compounded Profit Growth
- 10 Years
- +11%
- 5 Years
- +1%
- 3 Years
- +11%
- TTM
- +46%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- -6%
- 3 Years
- +12%
- 1 Year
- +16%
Return on Equity
- 10 Years
- +19%
- 5 Years
- +15%
- 3 Years
- +13%
- Last Year
- +14%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 48.87% | 48.86% | 48.86% | 47.82% | -1.04 pp |
| FII | 11.68% | 10.43% | 11.03% | 11.67% | +0.64 pp |
| DII | 34.73% | 35.80% | 35.12% | 35.49% | +0.37 pp |
| Public | 4.69% | 4.92% | 5.00% | 5.02% | +0.02 pp |
Filed with NSE for Sept 2026: promoters 47.82%, public 52.18%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 33.09% (+0.42 pp)- Promoters47.8%
- Foreign institutions11.7%
- Mutual funds33.1%
- Insurance2.0%
- Other domestic institutions0.4%
- Retail3.3%
- Others1.7%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Kotak Small Cap Fund | 3.12% | 1.94% | -0.02 pp |
| HDFC Focused Fund | 3.07% | 1.38% | -0.04 pp |
| HDFC Flexi Cap Fund | 2.93% | 0.32% | -0.02 pp |
| Franklin India Small Cap Fund | 2.30% | 2.06% | +0.30 pp |
| Nippon India Small Cap Fund | 2.10% | 0.33% | -0.01 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026. Adjusted for 1 corporate action.
Risk
- Volatility (1Y)
- 29.4%
- Downside volatility
- 26.5%
- Worst 5% of days
- 2.7%
- Average of that tail
- 3.6%
- Max drawdown (1Y)
- 20.9%
- Below its peak
- 6.3%
Against the market
- Beta vs Nifty 50
- 0.41
- Correlation
- 0.19
- Relative strength (3M)
- -1.4%
- ATR (14)
- 3.3%
Return
- Return 1M
- +6.4%
- Return 3M
- +2.5%
- Return 6M
- +11.2%
- Return 1Y
- +16.7%
- vs 200-day average
- +7.1%
Momentum
- RSI (14)
- 52.0
- MACD histogram
- 0.99
- Stochastic %K
- 46.4
- ADX (14)
- 27.9
- +DI / −DI
- 19.7 / 12.2
- Money flow index
- 71.4
Participation
- Delivery (20d avg)
- 53.8%
- vs its 60-day baseline
- -1.1 pts
- Volume vs 20-day
- -0.3σ
- Close vs day's VWAP
- -0.2%
- 52-week position
- 79 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
6 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- ₹300 Cr
- FCF yield
- 2.6%
- Cash conversion
- 1.83
- Accruals ratio
- -0.075
- Net debt
- ₹199 Cr
- Net debt / equity
- 0.12
- EV / sales
- 6.70
- Capex intensity
- 3.1%
- Revenue CAGR
- 27.4%
- Profit CAGR
- 88.1%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Metz Advisory LLP Promoter · Market Sale | Sell | 10,50,000 | ₹59.2 Cr | 13 Aug 2026 |
Duru Shah Family Trust Promoter Group · Market Sale | Sell | 10,50,000 | ₹59.2 Cr | 13 Aug 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividendNot available — not reported in this filing
Interim Dividend - Re 1 Per Share
9 Nov 2026ex-date - dividendNot available — not reported in this filing
Interim Dividend - Re 1 Per Share
19 May 2026ex-date - bonusNot available — not reported in this filing
Bonus 3:1
20 Mar 2026ex-date - dividend₹4.00
Interim Dividend - Rs 4 Per Share
11 Nov 2025ex-date - dividend₹4.00
Interim Dividend - Rs 4 Per Share
17 Nov 2023ex-date - otherNot available — not reported in this filing
Annual General Meeting
10 Aug 2023ex-date - dividend₹8.00
Interim Dividend - Rs 8 Per Share
23 Feb 2023ex-date - otherNot available — not reported in this filing
Annual General Meeting
8 Aug 2022ex-date - dividend₹8.00
Interim Dividend - Rs. 8 Per Share
21 Feb 2022ex-date - dividend₹8.00
Interim Dividend - Rs 8 Per Share
17 Feb 2021ex-date - dividend₹8.00
Interim Dividend - Rs 8 Per Share
13 Feb 2020ex-date
Company announcements
Allotment of 9,516 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020
Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026
Business update for Q2FY27
Allotment of 66,312 equity shares under the Metropolis- Restrictive Stock Unit Plan, 2020
Disclosure under Regulation 30 of SEBI Listing Regulations
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Franklin Templeton Mutual Fund
Transcript of Investors & Analyst Meet held on Thursday, August 27, 2026
Audio recording of the Investors & Analyst Meet
Disclosure under Regulation 30 of SEBI Listing Regulations
Investor Presentation
Disclosure under Regulation 30 of SEBI Listing Regulations
Schedule of Analyst / Institutional Investor Meeting
Scrutinizer's Report for the 26th Annual General Meeting
Proceedings of the 26th Annual General Meeting of the Company
Filed with BSE (scrip 542650); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Sep 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlides
- Nov 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 22 Sep from crisil
- Rating update · 24 Sep 2025 from crisil
- Rating update · 27 Sep 2024 from crisil
- Rating update · 17 Sep 2024 from crisil
- Rating update · 3 Oct 2023 from crisil
- Rating update · 10 Oct 2022 from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Metropolis Healthcare: common questions
Answered from the figures on this page.